Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

751
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
751
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

493
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
493
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

481
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of parabens, individually and in mixture, on human neutrophil oxidative burst under physiological and hyperglycemic conditions.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2026
Same author

Strengthening animal welfare: monitoring humane endpoints in a rat model of mammary tumorigenesis undergoing a ladder resistance training protocol.

Laboratory animals·2026
Same author

Uncovering urinary proteogenomic signatures associated with head and neck squamous cell carcinoma.

Molecular omics·2026
Same author

CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape.

Cell communication and signaling : CCS·2026
Same author

Aβ Modulates Extracellular Vesicles Proteomic Profile Impacting Phosphorylation Mediators.

Molecular neurobiology·2025
Same author

Ultrasound innovations in diaphragm assessment: an integrative review of expanding clinical applications.

European respiratory review : an official journal of the European Respiratory Society·2025

Related Experiment Video

Updated: Apr 27, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.1K

Biomarkers for cardiac cachexia: reality or utopia.

Telma Martins1, Rui Vitorino1, Francisco Amado2

  • 1Mass Spectrometry Group, QOPNA, Department of Chemistry, University of Aveiro, Portugal.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|July 1, 2014
PubMed
Summary

Cardiac cachexia, a complication of heart failure, involves significant weight loss. Multimarker strategies are crucial for diagnosing and managing this condition due to the limitations of individual biomarkers.

Keywords:
Chronic heart failureHormonal markersInflammationMultimarker strategyWasting

More Related Videos

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.1K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Related Experiment Videos

Last Updated: Apr 27, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.1K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.1K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Area of Science:

  • Cardiology
  • Biochemistry
  • Pathophysiology

Background:

  • Cardiac cachexia is a severe complication of chronic heart failure (CHF), marked by substantial weight loss and body wasting.
  • Muscle wasting in CHF stems from an imbalance in anabolic and catabolic pathways, driven by immunological, metabolic, and neurohormonal changes.
  • Lack of a universal definition and specific biomarkers hinders diagnosis and treatment of cardiac cachexia.

Purpose of the Study:

  • To review and analyze proposed biomarkers for cardiac cachexia.
  • To highlight the biological processes associated with these biomarkers.
  • To emphasize the need for multimarker strategies in diagnosing and managing cardiac cachexia.

Main Methods:

  • Integrated analysis of existing literature on cardiac cachexia biomarkers.
  • Review of hormonal, inflammatory, and oxidative stress molecules as potential serological markers.
  • Examination of biological processes modulated by cardiac cachexia.

Main Results:

  • Individual biomarkers for cardiac cachexia have shown limited success due to insufficient sensitivity and specificity.
  • Proposed biomarkers include hormonal, inflammatory, and oxidative stress molecules.
  • Biological processes implicated in cardiac cachexia are complex and multifactorial.

Conclusions:

  • Multimarker strategies are essential for improving the diagnosis and management of cardiac cachexia.
  • Integrated biomarker approaches can aid in identifying new therapeutic targets for cardiac cachexia.
  • Further research into multimarker panels is needed to effectively address the challenges of cardiac cachexia.